

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549

November 22, 2021

Mark Litton, Ph.D. Chief Executive Officer Athira Pharma, Inc. 18706 North Creek Parkway Suite 104 Bothell, WA 98011

Re: Athira Pharma, Inc.
Registration Statement on Form S-3
Filed November 15, 2021
File No. 333-261073

Dear Dr. Litton:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Christine Westbrook at 202-551-5019 with any questions.

Sincerely,

Division of Corporation Finance Office of Life Sciences

cc: Bryan King, Esq.